Chardan Capital restated their buy rating on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $20.00 price objective on the stock.
Orchestra BioMed Price Performance
OBIO stock opened at $7.94 on Wednesday. Orchestra BioMed has a one year low of $4.22 and a one year high of $14.19. The stock has a market cap of $284.17 million, a PE ratio of -5.36 and a beta of 0.42. The firm has a 50 day simple moving average of $5.50 and a two-hundred day simple moving average of $6.58.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Orchestra BioMed had a negative net margin of 2,330.46% and a negative return on equity of 70.18%. The business had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.28 million. On average, research analysts expect that Orchestra BioMed will post -1.58 EPS for the current fiscal year.
Insider Transactions at Orchestra BioMed
Institutional Investors Weigh In On Orchestra BioMed
An institutional investor recently bought a new position in Orchestra BioMed stock. Catalytic Wealth RIA LLC acquired a new position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,261 shares of the company’s stock, valued at approximately $117,000. Catalytic Wealth RIA LLC owned approximately 0.06% of Orchestra BioMed at the end of the most recent quarter. 53.55% of the stock is owned by institutional investors and hedge funds.
Orchestra BioMed Company Profile
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Further Reading
- Five stocks we like better than Orchestra BioMed
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Autodesk’s Quarterly Results Could Drive It Back to Recent Highs
- Learn Technical Analysis Skills to Master the Stock Market
- A Bubble is Brewing in Oracle Stock, and it’s Only Getting Bigger
- How to Read Stock Charts for Beginners
- Danaos Benefits from Increasing Demand in Container Shipping
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.